Index Investing News
Thursday, May 29, 2025
No Result
View All Result
  • Login
  • Home
  • World
  • Investing
  • Financial
  • Economy
  • Markets
  • Stocks
  • Crypto
  • Property
  • Sport
  • Entertainment
  • Opinion
  • Home
  • World
  • Investing
  • Financial
  • Economy
  • Markets
  • Stocks
  • Crypto
  • Property
  • Sport
  • Entertainment
  • Opinion
No Result
View All Result
Index Investing News
No Result
View All Result

Another CRISPR approval not likely ‘any time soon’ – report (NASDAQ:CRSP)

by Index Investing News
December 30, 2023
in Markets
Reading Time: 2 mins read
A A
0
Home Markets
Share on FacebookShare on Twitter


Bill Oxford/iStock via Getty Images

Following the recent FDA green light for the gene therapy Casgevy, “it is unlikely” that approval of a similar product will take place “any time soon,” according to a report by GlobalData.

According to GlobalData, only 24 CRISPR-based drugs are in Phase 2 trials, with 88% of such drugs in earlier-stage or preclinical development.

CRISPR and partner Vertex Pharmaceuticals (VRTX) made history earlier this month when Casgevy became the first FDA-approved treatment utilizing CRISPR gene-editing technology. The product was approved for the treatment of sickle cell anemia and is awaiting approval for transfusion-dependent thalassemia.

“The Casgevy approvals represent a significant milestone for revolutionary genome editing systems,” Jasper Morley, drugs intelligence analyst at GlobalData, stated. “However, given the relative immaturity of the CRISPR drugs pipeline, which features very few late-stage products alongside a low likelihood of approvals, it is unlikely to see another drug approval in the near future.”

In its report, published earlier this week, GlobalData listed the CRISPR Therapeutics (NASDAQ:CRSP) drug candidate CTX-110 as the likely next CRISPR-based gene therapy to be globally launched, possibly towards the end of 2025.

That estimate seems based on the fact that CTX-110 was further down the pipeline than most other CRISPR-related prospects, as it had reached Phase 2 development for B-cell malignancies. However, even GlobalData gave the product a relatively thin chance of eventually reaching the market, saying it had less than 50/50 odds of making a Phase 3 trial and only a 31% chance of approval.

Meanwhile, in early December, CRSP announced that it was shifting its focus from CTX-110 and another prospect, CTX-130, to other potential therapies, namely CTX-112 and CTX-131.

“We are very encouraged by the progress and early clinical data from our next-generation candidates. While we saw benefits from consolidation dosing with CTX110, we believe CTX112 could result in even better outcomes for patients,” said PK Morrow, CRSP’s chief medical officer said in a Dec. 4 press release.

Editor’s note: The framing of this story has been changed from its original version to more accurately describe the likely potential timeline for future CRISPR approvals. The story has been updated to provide significant additional context regarding CTX-110, including the pipeline update provided by the company earlier this month.

More on CRISPR Therapeutics



Source link

Tags: ApprovalCRISPRNASDAQCRSPReportTime
ShareTweetShareShare
Previous Post

US judge allows FTC to temporarily block IQVIA acquisition of DeepIntent By Reuters

Next Post

Arrests of Catholic priests in Nicaragua tick up as dragnet intensifies By Reuters

Related Posts

FL Infographic: Foot Locker slips to loss in Q1 2025; income down 5%

FL Infographic: Foot Locker slips to loss in Q1 2025; income down 5%

by Index Investing News
May 29, 2025
0

Foot Locker, Inc. (NYSE: FL), a number one footwear and attire retailer, reported a web loss for the primary quarter of...

China’s EV worth battle is heating up. What’s behind the large reductions?

China’s EV worth battle is heating up. What’s behind the large reductions?

by Index Investing News
May 29, 2025
0

Clients take a look at BYD electrical automobiles at an auto present in Yantai, in japanese China's Shandong province on...

Fed apprehensive it may face ‘troublesome tradeoffs’ if tariffs reaggravate inflation, minutes present

Fed apprehensive it may face ‘troublesome tradeoffs’ if tariffs reaggravate inflation, minutes present

by Index Investing News
May 29, 2025
0

Federal Reserve officers at their assembly earlier this month apprehensive that tariffs may worsen inflation and create a troublesome quandary...

Earnings Preview: Robust outcomes anticipated as Broadcom prepares for Q2 report

Earnings Preview: Robust outcomes anticipated as Broadcom prepares for Q2 report

by Index Investing News
May 28, 2025
0

Broadcom, Inc. (NASDAQ: AVGO), a market chief in semiconductor and infrastructure software program, shall be reporting second-quarter outcomes subsequent week...

Palantir groups up with Fannie Mae in AI push to smell out mortgage fraud

Palantir groups up with Fannie Mae in AI push to smell out mortgage fraud

by Index Investing News
May 29, 2025
0

Alex Karp, CEO of Palantir Applied sciences, speaks in the course of the Digital X occasion in Cologne, Germany, on...

Next Post
Arrests of Catholic priests in Nicaragua tick up as dragnet intensifies By Reuters

Arrests of Catholic priests in Nicaragua tick up as dragnet intensifies By Reuters

How Yemen Changed Everything – FREEDOMBUNKER

How Yemen Changed Everything – FREEDOMBUNKER

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED

Funds Blowout: New Biden Proposal Consists of Large Will increase In Navy, Future Pandemic Spending, Taxing The Wealthy

Funds Blowout: New Biden Proposal Consists of Large Will increase In Navy, Future Pandemic Spending, Taxing The Wealthy

March 29, 2022
Danielle Fishel Stuns Rider Sturdy With 30 Yr Secret: Watch – Hollywood Life

Danielle Fishel Stuns Rider Sturdy With 30 Yr Secret: Watch – Hollywood Life

August 27, 2022
AFC Wimbledon’s recreation with Crewe off after various venue couldn’t be discovered

AFC Wimbledon’s recreation with Crewe off after various venue couldn’t be discovered

September 25, 2024
Who to back at The 151st Open? Players to follow for potential major win at Royal Liverpool | Golf News

Who to back at The 151st Open? Players to follow for potential major win at Royal Liverpool | Golf News

July 19, 2023
Xi Jinping’s China and the rise of the ‘global west’

Xi Jinping’s China and the rise of the ‘global west’

October 24, 2022
BBC journalist shares Bukayo Saka return twist out of Arsenal

BBC journalist shares Bukayo Saka return twist out of Arsenal

March 28, 2025
How to Build Wealth in Three Simple Steps

How to Build Wealth in Three Simple Steps

April 24, 2023
Inventory futures slip after Nasdaq’s rally as traders digest company earnings

Inventory futures slip after Nasdaq’s rally as traders digest company earnings

July 21, 2022
Index Investing News

Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.

  • 1717575246.7
  • Browse the latest news about investing and more
  • Contact us
  • Cookie Privacy Policy
  • Disclaimer
  • DMCA
  • Privacy Policy
  • Terms and Conditions
  • xtw18387b488

Copyright © 2022 - Index Investing News.
Index Investing News is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • World
  • Investing
  • Financial
  • Economy
  • Markets
  • Stocks
  • Crypto
  • Property
  • Sport
  • Entertainment
  • Opinion

Copyright © 2022 - Index Investing News.
Index Investing News is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In